CTOs on the Move

Prologin Technologies Inc

www.prologin.com

 
Prologin Technologies Inc is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Klox Technologies

Klox Technologies is a Canadian specialty pharmaceutical company focusing on the development and commercialization of its proprietary BioPhotonic technology platform. This non-invasive, pathology-specific topical treatment platform harnesses the power of light and photo activated oxygen-rich gel formulations to target various skin and soft tissue disorders. With franchises in dermatology, wound care, and oral health, Klox Technologies is well positioned to capitalize on significant market opportunities. We believe that our dedication to providing healthcare professionals with novel and effective treatment solutions will allow patients to experience positive results without some of the side effects associated with existing treatments. Klox Technologies’ senior management team has over 80 years of combined experience in the biotechnology, pharmaceutical, and medical devices industries. We continue to research, develop, and commercialize solutions based on our BioPhotonic technology platform for a growing and aging population that is seeking more effective and less invasive treatment options to improve their health and quality of life.

Fraunhofer Center for Molecular Biology

Fraunhofer Center for Molecular Biology is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Provident Clinical Research and Consulting

Provident Clinical Research and Consulting is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Myriad RBM

Myriad RBM is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aro Biotherapeutics

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.